[go: up one dir, main page]

WO2016195089A1 - Promoteur de la salivation, inhibiteur de xérostomie, agent d'hydratation de la cavité buccale, et compositions - Google Patents

Promoteur de la salivation, inhibiteur de xérostomie, agent d'hydratation de la cavité buccale, et compositions Download PDF

Info

Publication number
WO2016195089A1
WO2016195089A1 PCT/JP2016/066641 JP2016066641W WO2016195089A1 WO 2016195089 A1 WO2016195089 A1 WO 2016195089A1 JP 2016066641 W JP2016066641 W JP 2016066641W WO 2016195089 A1 WO2016195089 A1 WO 2016195089A1
Authority
WO
WIPO (PCT)
Prior art keywords
oral
extract
salt
polyglutamic acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2016/066641
Other languages
English (en)
Japanese (ja)
Inventor
祟郎 岩井
物井　則幸
苗穂 鈴木
晶子 曽我
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lion Corp
Original Assignee
Lion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Corp filed Critical Lion Corp
Priority to CN201680031861.3A priority Critical patent/CN107613999B/zh
Priority to KR1020177026591A priority patent/KR20180011058A/ko
Priority to JP2017522290A priority patent/JP6841222B2/ja
Publication of WO2016195089A1 publication Critical patent/WO2016195089A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/88—Polyamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention relates to a saliva secretion promoter, a mouth dryness inhibitor, a mouth moisture additive, and a composition.
  • ⁇ Dry mice have abnormal saliva quality due to a decrease in saliva production, dry thirst and dry mouth, causing pain and discomfort. It is accompanied by sticky discomfort, difficulty in conversation, and bad breath. Furthermore, when it becomes pathological, not only oral function but also general health failure such as caries, periodontal disease, various infectious diseases, etc. occurs due to changes in oral flora.
  • Symptomatic treatment includes moisturizing the oral cavity with artificial saliva, oral moisturizer / humectant, etc., but it is not a fundamental solution. Therefore, it is important to promote saliva secretion and moisturize the oral cavity in order to keep the oral cavity refreshed and prevent oral diseases and systemic diseases.
  • salivary secretion promoter include polyglutamic acid and salts thereof, but a technique having a superior salivary secretion promoting effect has been desired.
  • the present invention has been made in view of the above circumstances, and an object of the present invention is to provide a salivary secretion promoter, a mouth dryness inhibitor, a mouth moisture additive, and an oral and oral composition that are effective in improving dry mice.
  • the present inventors have promoted salivation by using polyglutamic acid and / or a salt thereof and an Asparathus linearis extract in combination. It has been found that the dryness inside is soft and the sticky discomfort is removed, and the present invention has been made.
  • a salivary secretion promoter comprising (A) polyglutamic acid and / or a salt thereof and (B) an extract of Asparathus linearis as active ingredients.
  • An oral dryness inhibitor containing, as active ingredients, (A) polyglutamic acid and / or a salt thereof and (B) an extract of Asparathus linearis.
  • An intraoral moisture imparting agent comprising (A) polyglutamic acid and / or a salt thereof and (B) an extract of Asparathus linearis as active ingredients.
  • An oral composition for promoting saliva secretion or an oral composition for promoting saliva secretion comprising (A) polyglutamic acid and / or a salt thereof and (B) an extract of Asparathus lineias as active ingredients.
  • An oral composition for inhibiting oral dryness or an oral composition for inhibiting oral dryness comprising (A) polyglutamic acid and / or a salt thereof and (B) an extract of Asparathus linearis as active ingredients.
  • An oral composition for imparting oral moisture or an oral composition for imparting oral moisture containing (A) polyglutamic acid and / or a salt thereof and (B) an extract of Asparathus linearis as active ingredients object. [8].
  • (A) The content of polyglutamic acid and / or a salt thereof is 0.001 to 50% by mass, and the content of (B) Asparathus linearis extract is 0.0001 to 80% by mass
  • the present invention relates to a salivary secretion promoter, an oral dry inhibitor, and an oral moisture additive containing (A) polyglutamic acid and / or a salt thereof, and (B) an extract of Asparathus linearis as active ingredients. Provide the agent.
  • polyglutamic acid chemically synthesized ⁇ or ⁇ -polyglutamic acid, natural ⁇ or ⁇ -polyglutamic acid obtained as a fermentation product from various strains, or a salt thereof can be used.
  • natural polyglutamic acid is preferable because it is blended into oral compositions and foods, and ⁇ -polyglutamic acid that can be industrially mass-produced is most preferable.
  • Polyglutamic acid may be D-form or L-form. Polyglutamic acid is insoluble in water, but becomes water-soluble when converted to a salt.
  • Examples of the salt at this time include sodium salt, potassium salt, magnesium salt, calcium salt, ammonium salt, ethanolamine salt, basic amino acid salt and the like, and sodium or potassium salt is preferable.
  • the degree of neutralization of the salt used in the present invention can be arbitrarily selected according to the purpose when the aqueous solution having a concentration of 1% by mass is in the range of pH 1 to pH 14.
  • the viscosity of polyglutamic acid or a salt thereof is not particularly limited, and those having various viscosities can be used depending on the type of product, but the viscosity of a 4% by mass aqueous solution measured by the method described later is preferably 10 to 200 mPa ⁇ s. More preferably, it is in the range of 30 to 120 mPa ⁇ s.
  • ⁇ Viscosity measurement method> To a 200 mL beaker, take 96 g of water and add 4.0 g of polyglutamic acid or a salt thereof to a 200 mL beaker while stirring with a stirrer to completely dissolve it. Next, after leaving still in a 25 degreeC thermostat for 1 hour, the viscosity after 1 minute is measured correctly using the following BL type
  • BL type viscometer Tokyo Keiki: B type viscometer, model: BL, rotor: No. 2. Rotation speed: 60rpm, Measurement temperature: 25 ° C
  • polyglutamic acid or a salt thereof can be used as polyglutamic acid or a salt thereof.
  • ⁇ -polyglutamic acid sodium Meiji polyglutamic acid manufactured by Meiji Food Materia Co., Ltd. can be used.
  • Asparathus linearis extract Asparathus linealis is also called rooibos (hereinafter sometimes abbreviated as “rooibos”), and belongs to the genus Asparatus (Fabaceae).
  • the rooibos extract can be easily obtained by a method generally used for plant extraction, and the extraction method is not particularly limited as long as the effect of the present invention is obtained.
  • commercially available rooibos tea extract powder can be used.
  • the rooibos extraction site is not particularly limited and can be appropriately selected.
  • a leaf part, a young leaf part, a branch part, a trunk part, a bark part, a flower part, a fruit part, a root part, etc. are mentioned.
  • a young leaf part and a branch part are preferable.
  • the rooibos used for extraction can be either fermented or unfermented.
  • the fermented product refers to a product produced through an oxidation process
  • the unfermented product refers to this oxidation process, that is, a product that does not undergo fermentation.
  • the oxidation process of fermentation is not particularly limited, and a generally used method can be used. For example, it refers to an oxidation process in which water is contained and incubated at 20 to 40 ° C., or an oxidation process under sunlight.
  • the rooibos extract can be obtained by further subjecting to a solvent extraction described later after a pulverization process using a crusher, a drying process, or a combination thereof.
  • the drying process is not particularly limited, and a generally used method can be used. For example, it is preferable to carry out at 60 degrees C or less.
  • the extraction method is not particularly limited and can be appropriately selected.
  • the extraction part of rooibos as an extraction raw material is put into a treatment tank filled with an extraction solvent, and after eluting soluble components while stirring as necessary, the extract is removed by filtration to remove the extraction residue. Obtainable.
  • the extraction solvent is not particularly limited and can be appropriately selected.
  • water, a hydrophilic solvent, a hydrophobic solvent, or a mixed solvent thereof can be used.
  • water include pure water, tap water, well water, mineral water, mineral water, hot spring water, spring water, fresh water, purified water, hot water, ion exchange water, physiological saline, phosphate buffer, phosphate buffered physiological. Examples include saline.
  • hydrophilic solvent examples include lower alcohols having 1 to 6 carbon atoms such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; 1,3-butylene glycol, propylene glycol, glycerin, and the like. And polyhydric alcohols having 2 to 6 carbon atoms.
  • hydrophobic solvent examples include aromatic carbons such as benzene and toluene; organic solvents such as ethyl acetate, acetonitrile and ether; halogenated carbons such as dichloromethane and chloroform.
  • the said water, the said hydrophilic solvent, etc. can be mixed suitably and used.
  • the ratio of the mixed solvent is preferably 1 to 90 parts by mass of lower alcohol, lower aliphatic ketone, polyhydric alcohol and the like with respect to 10 parts by mass of water.
  • the extraction solvent is preferably water, ethanol, or a mixture of water and ethanol, more preferably a 0 to 20% by weight aqueous ethanol solution, and even more preferably water.
  • the amount of the extraction solvent used is not particularly limited and can be appropriately selected according to the extraction solvent, the extraction method, and the like. For example, 1 to 1,000 parts by mass of the extraction solvent can be used per 1 part by mass of the extraction site.
  • Extraction conditions are not particularly limited, and can be appropriately selected according to an extraction method such as an extraction solvent.
  • the solvent is water
  • the extraction temperature is preferably room temperature to hot water, more preferably hot water.
  • the rooibos extract can be purified and used as necessary, and the purification method is not particularly limited and can be appropriately selected.
  • purification methods such as liquid-liquid partition extraction, various types of chromatography, membrane separation, and supercritical fluid extraction can be mentioned.
  • the specific embodiment of the rooibos extract is not particularly limited and can be appropriately selected.
  • the extract itself the dried extract, the diluted extract, the dried extract, and the extract
  • a concentrated solution (concentrated extract), a dried product of an extract concentrate, a dried product powder, and the like can be used.
  • the extract a water extract is preferable, and a hot water extract is particularly preferable.
  • rooibos extract for example, a commercially available rooibos tea extract can also be used.
  • examples of commercially available rooibos tea extract include powder obtained by filtering hot water extract of rooibos fermented young leaves and concentrating and drying the filtrate.
  • salivary secretion promoter The combination of the above (A) polyglutamic acid and / or salt thereof and (B) rooibos extract provides a remarkable salivary secretion promoting effect that cannot be obtained independently.
  • This invention provides the salivary secretion promoter which uses this as an active ingredient.
  • the amount of polyglutamic acid and / or a salt thereof and (B) rooibos extract to each agent is appropriately selected depending on the dosage form, intake (administration) form, and intake (administration) target.
  • the effective amount of each agent for promoting saliva secretion and the like exerting the intended effect is as follows, and is appropriately selected from the state of the subject of intake (administration), age, and the like.
  • the effective amount of polyglutamic acid and / or a salt thereof is preferably 0.01 to 5,000 mg / day, more preferably 0.05 to 1,000 mg / day per day per adult. More preferably, it is 1 to 500 mg / day. Further, the number of intake (administration) is not limited, and can be ingested (administered) 1 to 20 times a day.
  • the effective amount of rooibos extract is, for example, preferably 1 to 10,000 mg / day, more preferably 10 to 1,000 mg / day, and further 20 to 500 mg / day. preferable. Such an amount may be taken (administered) once a day, or may be taken (administered) in a plurality of times (1 to 20 times) per day. When taking (administering) in multiple doses, it is preferably 5 to 50,000 mg / dose, more preferably 50 to 10,000 mg / dose, more preferably 100 to 5,000 mg in terms of dry rooibos before extraction. / Times is more preferable.
  • the method for taking (administering) the agent of the present invention is not particularly limited, and it may be oral or parenteral.
  • the dosage form is not particularly limited, and a solid, liquid, gel, cream, paste or the like can be appropriately selected.
  • oral is preferred, and known dosage forms such as powders, tablets, orally disintegrating tablets, chewable tablets, capsules, films, sprays, and liquids can be selected.
  • the solid may be taken up (administered) by dissolving it in a liquid such as water or diluting the liquid with water.
  • a liquid such as water or diluting the liquid with water.
  • orally disintegrating tablets, chewing tablets, and sprays are preferable.
  • the present invention provides an oral or oral composition containing (A) polyglutamic acid and / or a salt thereof and (B) an extract of Asparathus linearias.
  • A polyglutamic acid and / or a salt thereof
  • B an extract of Asparathus linearias.
  • the above-mentioned agent or Asparathus linearis extract is used as an active ingredient, for salivary secretion promotion, for oral dry suppression, for oral moisture provision It is suitable as a composition for oral cavity or internal use.
  • the content of (A) polyglutamic acid and / or a salt thereof in the composition is preferably 0.001 to 50% by mass, and more preferably 0.01 to 10% by mass.
  • the content of Aspalathus linearis extract (equivalent to dry matter) is preferably 0.0001 to 80% by mass, more preferably 0.001 to 70% by mass, and 0.01 to 60% More preferred is mass%.
  • the blending mass ratio of component (B) to component (B) is preferably 0.001 to 1,000 / 1, and more preferably 0.01 to 100/1. When this ratio is smaller than 0.001 / 1, there is a possibility that the effect of suppressing dry mouth is inferior. On the other hand, when it is larger than 1,000 / 1, the effect of imparting moisture in the oral cavity may be inferior.
  • the dosage form is preferably a solid agent such as a tablet such as an orally disintegrating tablet or a chewable tablet, preferably 0.001 to 1,000 / 1, more preferably 0.002 to 100/1, 0.005 to 10/1 is more preferable.
  • a liquid agent such as a spray
  • 0.001 to 1,000 / 1 is preferable, 1 to 100/1 is more preferable, and 50 to 100/1 is further preferable.
  • the oral composition is “mainly intended for use in the oral cavity” and includes (i) ingestible and (ii) discharged after use. Specifically (i) what can be ingested includes troches, mouth freshener compositions, and the like. (Ii) To be discharged after use, toothpaste compositions such as toothpastes, liquid dentifrices, liquid dentifrices, powder dentifrices, mouthwash compositions, gargle compositions, oral coating compositions , Oral pasta, denture stabilizer composition and the like. However, in some cases, the oral coating composition, the oral pasta, and the like can be ingested.
  • the internal composition is “mainly intended to be taken orally” and is not particularly limited, and examples thereof include pharmaceuticals, foods for specified health use, foods and the like.
  • Foods for specified health use or foods such as candy, chewing gum, ramune, gummy, etc. that stay in the mouth for a long time
  • beverages soft drinks, carbonated drinks, nutrition drinks, powdered drinks, fruit drinks, milk drinks, jelly drinks, etc.
  • Food staple foods (cereals such as rice and wheat, noodles, bread, cereals, etc.), confectionery, dairy products, processed products such as meat, fish, vegetables and fruits, seasonings, etc., are not particularly limited.
  • composition for oral cavity and the composition for internal use are each normal dosage form, and are not particularly limited. Solid, liquid, gel, cream, paste, etc. can be appropriately selected, and powder, tablet, orally disintegrating tablet can be selected. A chewable tablet, capsule, film, spray or the like can also be selected as appropriate.
  • the dosage form is preferably an orally disintegrating tablet, a chewable tablet, a spray, and the like.
  • an arbitrary amount of any component used in each preparation or composition can be blended within a range that does not impair the effects of the present invention.
  • optional components include excipients, diluents, buffers, fragrances, colorants, antifoaming agents, coating agents, corrigents, binders, surfactants, humectants, thickeners, lubricants, Suspending agents, preservatives, chelating agents, antioxidants, abrasives, thickeners, binders, pH adjusters, brighteners, drugs, solvents, and the like can be mentioned. Can be used in appropriate combination.
  • a viscous agent, a binder, a surfactant and the like can be blended.
  • an abrasive can be blended.
  • a surfactant, a solvent and the like can be blended.
  • the ingestion (administration) method of the agent and composition of the present invention is not particularly limited, may be appropriately selected, and may be determined when the oral cavity is dry or the number of times per day may be determined.
  • the number of times is not particularly limited, and is appropriately selected within a range of, for example, 1 to 20 times.
  • the present invention can further provide the following inventions.
  • the optimum components, amounts, etc. are the same as described above.
  • the composition for oral cavity or oral composition described above has a salivary secretion effect, an oral dry suppression effect, or an oral moisture. How to give a given effect.
  • Sodium polyglutamate is sodium ⁇ -polyglutamate (4% aqueous solution viscosity: 35.5 mPa ⁇ s (25 ° C)) manufactured by Meiji Food Materia Co., Ltd.
  • MF filtered rooibos fermented hot water extract of rooibos and concentrated and dried the filtrate, containing 10% rooibos extract and 90% dextrin
  • the amount of rooibos extract in Table 1 is a pure equivalent amount (corresponding to dry mass).
  • Examples 1 to 13 Tablets having the compositions shown in Tables 2 to 4 below were tableted by a direct compression method using a rotary tableting machine (LIBURA2 manufactured by Kikusui Seisakusho Co., Ltd.).
  • sodium polyglutamate is Meiji Polyglutamate ( ⁇ -polyglutamate, 4% aqueous solution viscosity: 35.5 mPa ⁇ s (25 ° C.)) manufactured by Meiji Food Materia Co., Ltd.
  • the fermented rooibos tea extract of the component the rooibos tea dry extract F manufactured by Maruzen Pharmaceutical Co., Ltd.
  • the non-fermented rooibos tea extract of the component is a green rooibos extract manufactured by Tama Seikagaku Co., Ltd. (which is a powder obtained by filtering a hot water extract of rooibos unfermented young leaves and concentrating and drying the filtrate.
  • surface is a pure component conversion amount (equivalent to dry mass). The following evaluation was performed about the obtained tablet.
  • Salivary secretion promoting action Sensory evaluation (5 persons) of salivary secretion promoting action was performed using a tablet. Specifically, one tablet was chewed and ingested, and evaluation was performed 60 minutes after swallowing. The “feeling that saliva secretion was promoted” was evaluated according to the following evaluation criteria. ⁇ Evaluation criteria> A: 5 out of 5 respondents felt that saliva secretion was promoted. ⁇ : 3 to 4 out of 5 responded that saliva secretion was promoted. ⁇ : 1 to 2 out of 5 respondents felt that saliva secretion was promoted. X: 0 out of 5 respondents felt that saliva secretion was promoted.
  • Oral dryness suppression effect A sensory evaluation (5 persons) of oral dryness suppression effect was performed using a tablet. Specifically, one tablet was chewed and ingested, and evaluation was performed 60 minutes after swallowing. The “feeling that drying in the oral cavity is suppressed” was evaluated according to the following evaluation criteria. ⁇ Evaluation criteria> A: 5 out of 5 respondents feel that dryness in the oral cavity is suppressed. ⁇ : 3 to 4 out of 5 respondents feel that dryness in the oral cavity is suppressed. ⁇ : 1 to 2 out of 5 respondents feel that dryness in the oral cavity is suppressed. X: 0 out of 5 respondents feel that dryness in the oral cavity is suppressed.
  • Examples 14 to 25, Comparative Examples 4 to 5 The sprays having the compositions shown in Tables 5 to 7 below were prepared by measuring each component and mixing with a stirrer. 30 g of the prepared liquid was filled into a spray container (Y-70 dispenser manufactured by Yoshino Kogyo Co., Ltd., nozzle hole 0.55 mm, spray amount of one push was about 0.07 mL, capacity 30 mL polyethylene terephthalate bottle). The following evaluation was performed about the obtained spray agent.
  • Salivary secretion promoting action A sensory evaluation (5 persons) of salivary secretion promoting action was performed using a spray agent. Specifically, the test preparation was sprayed into a 5 push (about 0.35 mL) mouth, and evaluation was performed 30 minutes later. The “feeling that saliva secretion was promoted” was evaluated according to the following evaluation criteria. ⁇ Evaluation criteria> A: 5 out of 5 respondents felt that saliva secretion was promoted. ⁇ : 3 to 4 out of 5 responded that saliva secretion was promoted. ⁇ : 1 to 2 out of 5 respondents felt that saliva secretion was promoted. X: 0 out of 5 respondents felt that saliva secretion was promoted.
  • Oral dryness inhibiting effect A sensory evaluation (5 persons) of the oral dryness inhibiting effect was performed using a spray agent. Specifically, the test preparation was sprayed into a 5 push (about 0.35 mL) mouth, and evaluation was performed 30 minutes later. The “feeling that dryness in the oral cavity is suppressed” was evaluated according to the following evaluation criteria. ⁇ Evaluation criteria> A: 5 out of 5 respondents feel that dryness in the oral cavity is suppressed. ⁇ : 3 to 4 out of 5 respondents feel that dryness in the oral cavity is suppressed. ⁇ : 1 to 2 out of 5 respondents feel that dryness in the oral cavity is suppressed. X: 0 out of 5 respondents feel that dryness in the oral cavity is suppressed.
  • the following examples showed excellent saliva secretion promoting effect, oral dryness inhibiting effect, and oral moisture moisturizing effect as in the above examples.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un promoteur de la salivation qui comprend en tant qu'ingrédients actifs de l'acide polyglutamique et/ou un sel de celui-ci et un extrait de Aspalathus linearis .
PCT/JP2016/066641 2015-06-04 2016-06-03 Promoteur de la salivation, inhibiteur de xérostomie, agent d'hydratation de la cavité buccale, et compositions Ceased WO2016195089A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201680031861.3A CN107613999B (zh) 2015-06-04 2016-06-03 唾液分泌促进剂、口腔干燥抑制剂及口腔内湿润赋予剂
KR1020177026591A KR20180011058A (ko) 2015-06-04 2016-06-03 타액 분비 촉진제, 구강 건조 억제제 및 구강내 물기 부여제, 및 조성물
JP2017522290A JP6841222B2 (ja) 2015-06-04 2016-06-03 唾液分泌促進剤、口腔乾燥抑制剤及び口腔内うるおい付与剤、及び組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015-113824 2015-06-04
JP2015113824 2015-06-04

Publications (1)

Publication Number Publication Date
WO2016195089A1 true WO2016195089A1 (fr) 2016-12-08

Family

ID=57441331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/066641 Ceased WO2016195089A1 (fr) 2015-06-04 2016-06-03 Promoteur de la salivation, inhibiteur de xérostomie, agent d'hydratation de la cavité buccale, et compositions

Country Status (4)

Country Link
JP (1) JP6841222B2 (fr)
KR (1) KR20180011058A (fr)
CN (1) CN107613999B (fr)
WO (1) WO2016195089A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105102A (ja) * 2018-12-27 2020-07-09 ライオン株式会社 固形組成物及びその製造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049050A1 (fr) * 2003-11-19 2005-06-02 Meiji Seika Kaisha, Ltd. Sialagogue et composition contenant ce compose, composition orale et composition alimentaire
JP2006117563A (ja) * 2004-10-20 2006-05-11 Shiiai Medical:Kk 口腔用組成物、及び、それを用いた口腔湿潤剤
JP2009256271A (ja) * 2008-04-18 2009-11-05 Maruzen Pharmaceut Co Ltd アクアポリン３ｍＲＮＡ発現促進剤及び皮膚水分保持機能改善剤
JP2015107925A (ja) * 2013-12-04 2015-06-11 ライオン株式会社 ムスカリン受容体活性化剤及び唾液分泌促進剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049050A1 (fr) * 2003-11-19 2005-06-02 Meiji Seika Kaisha, Ltd. Sialagogue et composition contenant ce compose, composition orale et composition alimentaire
JP2006117563A (ja) * 2004-10-20 2006-05-11 Shiiai Medical:Kk 口腔用組成物、及び、それを用いた口腔湿潤剤
JP2009256271A (ja) * 2008-04-18 2009-11-05 Maruzen Pharmaceut Co Ltd アクアポリン３ｍＲＮＡ発現促進剤及び皮膚水分保持機能改善剤
JP2015107925A (ja) * 2013-12-04 2015-06-11 ライオン株式会社 ムスカリン受容体活性化剤及び唾液分泌促進剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105102A (ja) * 2018-12-27 2020-07-09 ライオン株式会社 固形組成物及びその製造方法
JP7182457B2 (ja) 2018-12-27 2022-12-02 ライオン株式会社 固形組成物及びその製造方法

Also Published As

Publication number Publication date
KR20180011058A (ko) 2018-01-31
CN107613999B (zh) 2021-07-20
JPWO2016195089A1 (ja) 2018-03-22
JP6841222B2 (ja) 2021-03-10
CN107613999A (zh) 2018-01-19

Similar Documents

Publication Publication Date Title
CA2350450A1 (fr) Melange d'aromes destine au masquage du mauvais gout de composes de zinc
JP2013520518A (ja) 口腔ケア組成物
JP3241955B2 (ja) 口腔用組成物
JP2002029952A (ja) 歯磨用組成物
JPH08310931A (ja) グルコシルトランスフェラーゼ阻害剤および口腔清浄化剤
JP2006016390A (ja) プロアントシアニジン含有組成物
JP2021065176A (ja) 口腔内病原性細菌の生育抑制剤、口腔用組成物及び促進剤
JP5306626B2 (ja) 粉末製剤並びにそれを用いた食品素材及び化粧品素材
JPH08175945A (ja) 口腔用組成物
JP6841222B2 (ja) 唾液分泌促進剤、口腔乾燥抑制剤及び口腔内うるおい付与剤、及び組成物
JP6505358B2 (ja) 収斂用組成物
JP7333751B2 (ja) ヒト抗菌ペプチド産生促進剤
JP6249588B2 (ja) 口腔用組成物
WO2007020830A1 (fr) Composition orale
JP2017001957A (ja) 唾液分泌促進剤、口腔乾燥抑制剤及び口腔内うるおい付与剤、及び組成物
JP7409775B2 (ja) 低収斂性組成物
JP6628839B2 (ja) 収斂用組成物
KR100495030B1 (ko) 캡슐화된 생약추출물을 함유하는 구강위생 증진용 조성물
JP2001335498A (ja) 美白組成物及びそれを含む食品及び化粧品
JP2001321123A (ja) 抗う蝕性食品素材、およびその組成物
RU2777153C1 (ru) Композиция для ухода за полостью рта для пациентов с метаболическими нарушениями
KR102814752B1 (ko) 침샘 자극을 통한 구강 건조 완화능 및 구취 제거능을 갖는 파라크레스를 포함하는 구강 붕해 필름
JP4585066B2 (ja) う蝕防止剤、口腔用剤および飲食物
JP7784226B2 (ja) 口腔用組成物
JP7368858B2 (ja) バイオフィルム形成抑制剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16803520

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017522290

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20177026591

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16803520

Country of ref document: EP

Kind code of ref document: A1